Adjuvant Sutent improves disease-free survival in RCC

Pfizer Inc. (NYSE:PFE) said Sutent sunitinib met the primary endpoint of significantly improving disease-free survival vs. placebo in the Phase III S-TRAC study to treat patients at high risk of recurrent renal cell carcinoma following surgery. According to Pfizer, S-TRAC was the first RCC study to show a disease-free survival benefit with a tyrosine kinase inhibitor in an adjuvant setting.

The data disclosed Friday came from the cohort of ex-Chinese patients in the study, which enrolled over 670 patients to receive Sutent or placebo for one year. Pfizer said full study results will be presented at the European Society for Medical Oncology meeting in October. ...